FDA accuses Walmart, Target, Kroger and Alberstons of botched botulism recalls as infants got sick

Federal regulators have issued warning letters to Walmart, Target, Kroger and Albertsons after the retailers continued selling ByHeart infant formula for days or weeks following a Nov. 11 recall tied to a botulism outbreak that has sickened more than 50 infants in 19 states; the FDA reported the product was found at Target stores in 20 states (including sales in New Hampshire on Nov. 16 despite an electronic block and a promoted discount in Arkansas), at Walmart in 21 states (Nov. 12–26), Albertsons in 11 states (Nov. 12–19) and Kroger in 10 states (Nov. 12–19). The agency said the companies have not provided evidence of corrective actions and have 15 working days to respond, while retailers said they moved to block sales and remove product; the CDC has expanded the outbreak to include all infants treated for botulism after consuming ByHeart formula since production began in 2023. Public-health officials and industry observers also faulted the FDA for delayed distribution of product lists to state and local partners, a lapse that has intensified regulatory scrutiny and potential legal and reputational exposure across the supply chain.

Analysis

The U.S. Food and Drug Administration issued warning letters on Dec. 12 to Walmart, Target, Kroger and Albertsons for continuing to sell ByHeart infant formula after a Nov. 11 recall tied to a botulism outbreak that has sickened more than 50 babies in 19 states; the FDA said the retailers have not provided evidence of corrective actions and have 15 working days to respond. FDA field observations cited ByHeart found at Target stores in 20 states (including a Nov. 16 sale in New Hampshire despite an electronic sales block and a promoted discount in Arkansas Nov. 16–22), at Walmart in 21 states from Nov. 12–26, at Albertsons in 11 states Nov. 12–19 and at Kroger in 10 states Nov. 12–19. The CDC expanded the outbreak to include all infants treated for botulism after consuming ByHeart formula since production began in 2023, amplifying public-health and liability implications for the supply chain and retailers. Market signals show moderately negative sentiment overall and stronger downside pressure on Target (per-ticker sentiment -0.8), signaling elevated near-term reputational, regulatory and legal risk that will likely drive volatility in the affected retailers until remediation and FDA acceptance are documented.

Key Decisions for Investors

• Monitor each retailer’s formal FDA response and any submitted corrective-action evidence within the 15 working-day window and be prepared to adjust exposure if the responses are inadequate
• Consider reducing near-term exposure to Target given the specific violations cited (product in 20 states, sales after an electronic block) and its relatively stronger negative sentiment signal
• Favor names that have verifiable removal and remediation documentation (Walmart and Albertsons statements exist but should be confirmed with FDA correspondence) before adding risk, while maintaining defensive positioning across the retail basket
• Use short-term hedges or lower gross exposure to retail/consumer discretionary allocations until recall-related costs, potential litigation disclosures and consumer demand impacts are clearer
• Track regulatory filings, company disclosures of recall costs or inventory write-downs, and any class-action or enforcement actions as primary triggers for further portfolio action